In a filing, Viking Therapeutics Inc revealed its President & CEO Lian Brian unloaded Company’s shares for reported $1.35 million on Feb 09 ’24. In the deal valued at $29.90 per share,45,000 shares were sold. As a result of this transaction, Lian Brian now holds 2,139,882 shares worth roughly $162.37 million.
Then, Lian Brian sold 269,079 shares, generating $7,230,784 in total proceeds. Upon selling the shares at $26.87, the President & CEO now owns 2,184,882 shares.
Before that, Rouan Sarah Kathryn sold 25,000 shares. Viking Therapeutics Inc shares valued at $701,250 were divested by the Director at a price of $28.05 per share. As a result of the transaction, Rouan Sarah Kathryn now holds 0 shares, worth roughly $0.0.
Oppenheimer reiterated its Viking Therapeutics Inc [VKTX] rating to an Outperform in a research note published on March 26, 2024; the price target was $138. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. Oppenheimer also remained covering VKTX and reiterated its “an Outperform” recommendation on February 28, 2024.
Price Performance Review of VKTX
On Monday, Viking Therapeutics Inc [NASDAQ:VKTX] saw its stock fall -0.75% to $75.88. Over the last five days, the stock has lost -4.55%. Viking Therapeutics Inc shares have risen nearly 307.74% since the year began. Nevertheless, the stocks have risen 364.95% over the past one year. While a 52-week high of $99.41 was reached on 02/28/24, a 52-week low of $8.28 was recorded on 01/03/24. SMA at 50 days reached $56.47, while 200 days put it at $25.11. A total of 2.29 million shares were traded, compared to the trading of 2.34 million shares in the previous session.
Levels Of Support And Resistance For VKTX Stock
The 24-hour chart illustrates a support level at 74.34, which if violated will result in even more drops to 72.79. On the upside, there is a resistance level at 77.12. A further resistance level may holdings at 78.35. The Relative Strength Index (RSI) on the 14-day chart is 56.21, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 47.74%. Stochastics %K at 51.60% indicates the stock is a holding.
How much short interest is there in Viking Therapeutics Inc?
A steep rise in short interest was recorded in Viking Therapeutics Inc stocks on Mar 15, 2024, dropping by -0.88 million shares to a total of 11.14 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 12.02 million shares. There was a decline of -7.9%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 11.77% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.93.
The most recent change occurred on March 28, 2023 when Maxim Group resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $25.
